Cargando…

Correction to Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase Inhibitor

Detalles Bibliográficos
Autores principales:	Kim, Hyung-Gu, Tan, Li, Weisberg, Ellen L., Liu, Feiyang, Canning, Peter, Choi, Hwan-Geun, Ezell, Scott, Zhao, Zheng, Wu, Hong, Wang, Jinhua, Mandinova, Anna, Bullock, Alex N., Liu, Qingsong, Lee, Sam W., Gray, Nathanael S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2014
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3971954/ http://dx.doi.org/10.1021/cb5000949

Ejemplares similares

Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase Inhibitor
por: Kim, Hyung-Gu, et al.
Publicado: (2013)

Structural Mechanisms Determining Inhibition of the Collagen Receptor DDR1 by Selective and Multi-Targeted Type II Kinase Inhibitors
por: Canning, Peter, et al.
Publicado: (2014)

Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer
por: Terai, Hideki, et al.
Publicado: (2015)

Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma
por: Wu, Hong, et al.
Publicado: (2014)

Selective Akt Inhibitors Synergize with Tyrosine Kinase Inhibitors and Effectively Override Stroma-Associated Cytoprotection of Mutant FLT3-Positive AML Cells
por: Weisberg, Ellen, et al.
Publicado: (2013)

Identification of Receptor Tyrosine Kinase, Discoidin Domain Receptor 1 (DDR1), as a Potential Biomarker for Serous Ovarian Cancer
por: Quan, Jinhua, et al.
Publicado: (2011)

Repurposing of Kinase Inhibitors for Treatment of COVID-19
por: Weisberg, Ellen, et al.
Publicado: (2020)

Multikinase Abl/DDR/Src Inhibition Produces Optimal Effects for Tyrosine Kinase Inhibition in Neurodegeneration
por: Fowler, Alan J., et al.
Publicado: (2019)

Discovery of a highly potent and selective Bruton’s tyrosine kinase inhibitor avoiding impairment of ADCC effects for B-cell non-Hodgkin lymphoma
por: Liu, Juan, et al.
Publicado: (2020)

Molecular Drug Discovery of Single Ginsenoside Compounds as a Potent Bruton’s Tyrosine Kinase Inhibitor
por: Lee, Keun Woo, et al.
Publicado: (2020)

Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD(+) AML cell growth
por: Weir, Mark C., et al.
Publicado: (2017)

Discovery of 3,5-Diamino-1,2,4-triazole Ureas as Potent Anaplastic Lymphoma Kinase Inhibitors
por: Deng, Xianming, et al.
Publicado: (2011)

Discovery of Potent and Selective Tricyclic Inhibitors of Bruton’s Tyrosine Kinase with Improved Druglike Properties
por: Wang, Xiaojing, et al.
Publicado: (2017)

Cell-ECM interactions control DDR
por: Dickreuter, Ellen, et al.
Publicado: (2015)

Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?
por: Zhao, Zheng, et al.
Publicado: (2014)

The Journey of DDR1 and DDR2 Kinase Inhibitors as Rising Stars in the Fight Against Cancer
por: Elkamhawy, Ahmed, et al.
Publicado: (2021)

The tyrosine kinase inhibitor nilotinib targets the discoidin domain receptor DDR2 in calcific aortic valve stenosis
por: Carracedo, Miguel, et al.
Publicado: (2022)

Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignancies
por: Mei, Husheng, et al.
Publicado: (2023)

Discovery of 5-Phenoxy-2-aminopyridine Derivatives as Potent and Selective Irreversible Inhibitors of Bruton’s Tyrosine Kinase
por: Lee, Eun, et al.
Publicado: (2020)

Abemaciclib is a potent inhibitor of DYRK1A and HIP kinases involved in transcriptional regulation
por: Kaltheuner, Ines H., et al.
Publicado: (2021)

Tyrosine kinase-independent actions of DDR2 in tumor cells and cancer-associated fibroblasts influence tumor invasion, migration and metastasis
por: Barcus, Craig E., et al.
Publicado: (2021)

Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase
por: Moccia, Marialuisa, et al.
Publicado: (2015)

BMI1, ATM and DDR
por: Lin, Xiaozeng, et al.
Publicado: (2015)

Prevalence of Mutations in Discoidin Domain-Containing Receptor Tyrosine Kinase 2 (DDR2) in Squamous Cell Lung Cancers in Korean Patients
por: Lee, Mi-Sook, et al.
Publicado: (2017)

Discoidin Domain Receptor Tyrosine Kinase 1 (DDR1): A Novel Predictor for Recurrence of Hepatocellular Carcinoma After Curative Resection
por: Xu, Meng, et al.
Publicado: (2021)

Activation of transmembrane receptor tyrosine kinase DDR1-STAT3 cascade by extracellular matrix remodeling promotes liver metastatic colonization in uveal melanoma
por: Dai, Wei, et al.
Publicado: (2021)

Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in TNK2 and DDR1
por: Rudd, Meghan L, et al.
Publicado: (2014)

Activation of tyrosine kinases by mutation of the gatekeeper threonine
por: Azam, Mohammad, et al.
Publicado: (2008)

Inhibitors of Discoidin Domain Receptor (DDR) Kinases for Cancer and Inflammation
por: Denny, William A., et al.
Publicado: (2021)

Discoidin Domain Receptors, DDR1b and DDR2, Promote Tumour Growth within Collagen but DDR1b Suppresses Experimental Lung Metastasis in HT1080 Xenografts
por: Wasinski, Benjamin, et al.
Publicado: (2020)

Effect of Hypoxia on DDR1 Expression in Pituitary Adenomas
por: Li, Shouchun, et al.
Publicado: (2015)

Discovery of Anilino-1,4-naphthoquinones as Potent EGFR Tyrosine Kinase Inhibitors: Synthesis, Biological Evaluation, and Comprehensive Molecular Modeling
por: Mahalapbutr, Panupong, et al.
Publicado: (2022)

Discovery of Novel Naphthoquinone–Chalcone Hybrids as Potent FGFR1 Tyrosine Kinase Inhibitors: Synthesis, Biological Evaluation, and Molecular Modeling
por: Leechaisit, Ronnakorn, et al.
Publicado: (2023)

Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation
por: Wang, Aoli, et al.
Publicado: (2016)

Discoidin Domain Receptor 1 (DDR1) tyrosine kinase is upregulated in PKD kidneys but does not play a role in the pathogenesis of polycystic kidney disease
por: Soomro, Irfana, et al.
Publicado: (2019)

DdrA, DdrD, and PprA: Components of UV and Mitomycin C Resistance in Deinococcus radiodurans R1
por: Selvam, Kathiresan, et al.
Publicado: (2013)

Population-level diversity-disease relationship (p-DDR) in the human microbiome associated diseases
por: Li, Wendy, et al.
Publicado: (2021)

Characterization of selective and potent PI3Kδ inhibitor (PI3KD-IN-015) for B-Cell malignances
por: Liu, Xiaochuan, et al.
Publicado: (2016)

DDR1 key for cancer cell escape
por: Leslie, Mitch
Publicado: (2014)

Inside the hypoxic tumour: reprogramming of the DDR and radioresistance
por: Begg, Katheryn, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_l1iskruvais9oehpo82jdea9me